Therapeutic agent or treatment method for Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) having IKZF1 mutation

• 收藏
• 分享

专利权人:

发明人:

Kanji Sugita,Kiyoshi Ando

申请号：

US15758582

公开号：

US10314834B2

申请日:

2016.09.09

申请国别(地区):

US

年份:

2019

代理人:

摘要：

According to the present invention, there is provided a pharmaceutical composition for treating Philadelphia chromosome positive lymphocytic leukemia, including a thalidomide derivative and BCR-ABL tyrosine kinase inhibitor. According to the present invention there is also provided a method of treating Philadelphia chromosome positive lymphocytic leukemia, including administering a thalidomide derivative and a BCR-ABL tyrosine kinase inhibitor to a patient suffering from Philadelphia chromosome positive lymphocytic leukemia.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/